Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $19,835 | 1,233 | 38.5% |
| Consulting Fee | $14,430 | 6 | 28.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,400 | 15 | 27.9% |
| Travel and Lodging | $2,858 | 12 | 5.5% |
| Education | $58.06 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $18,693 | 185 | $0 (2024) |
| Allergan, Inc. | $6,723 | 63 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,997 | 58 | $0 (2024) |
| AstraZeneca AB | $3,444 | 3 | $0 (2020) |
| ABBVIE INC. | $3,375 | 124 | $0 (2024) |
| Novo Nordisk Inc | $1,341 | 84 | $0 (2024) |
| PFIZER INC. | $1,203 | 104 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,085 | 57 | $0 (2024) |
| Amgen Inc. | $956.81 | 51 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $853.22 | 61 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,293 | 166 | AstraZeneca Pharmaceuticals LP ($4,042) |
| 2023 | $10,415 | 153 | AstraZeneca Pharmaceuticals LP ($8,349) |
| 2022 | $2,206 | 147 | ABBVIE INC. ($283.55) |
| 2021 | $6,474 | 149 | AbbVie Inc. ($2,434) |
| 2020 | $9,962 | 153 | Allergan, Inc. ($4,380) |
| 2019 | $1,876 | 118 | AstraZeneca Pharmaceuticals LP ($565.05) |
| 2018 | $7,305 | 159 | Takeda Pharmaceuticals U.S.A., Inc. ($5,288) |
| 2017 | $7,049 | 229 | AstraZeneca Pharmaceuticals LP ($4,062) |
All Payment Transactions
1,274 individual payment records from CMS Open Payments — Page 51 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/31/2017 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Drug) | Food and Beverage | In-kind items and services | $8.11 | General |
| Category: DIABETES | ||||||
| 01/30/2017 | Arbor Pharmaceuticals, Inc. | Edarbi (Drug) | Food and Beverage | Cash or cash equivalent | $22.06 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/29/2017 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: RESPIRATORY | ||||||
| 01/26/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $11.89 | General |
| Category: DIABETES | ||||||
| 01/25/2017 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $88.66 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/25/2017 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug), FARXIGA, BEVESPI AEROSPHERE | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Respiratory | ||||||
| 01/24/2017 | Ironwood Pharmaceuticals, Inc | LINZESS (Drug), VIBERZI, ZURAMPIC | Food and Beverage | In-kind items and services | $10.65 | General |
| Category: Gastroenterology | ||||||
| 01/23/2017 | Arbor Pharmaceuticals, Inc. | Edarbi (Drug) | Food and Beverage | Cash or cash equivalent | $16.60 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/23/2017 | Merck Sharp & Dohme Corporation | ASMANEX (Drug), BELSOMRA, DULERA | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: RESPIRATORY | ||||||
| 01/17/2017 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug), XARELTO | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/16/2017 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: Respiratory | ||||||
| 01/13/2017 | Horizon Pharma plc | DUEXIS (Drug) | Food and Beverage | In-kind items and services | $3.66 | General |
| Category: DUEXIS | ||||||
| 01/12/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Urology | ||||||
| 01/12/2017 | Horizon Pharma plc | DUEXIS (Drug) | Food and Beverage | In-kind items and services | $5.10 | General |
| Category: DUEXIS | ||||||
| 01/10/2017 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Consulting Fee | Cash or cash equivalent | $901.00 | General |
| Category: Respiratory | ||||||
| 01/10/2017 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), JANUMET, JANUMET XR | Food and Beverage | In-kind items and services | $10.02 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/09/2017 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/09/2017 | Arbor Pharmaceuticals, Inc. | Edarbi (Drug) | Food and Beverage | Cash or cash equivalent | $15.30 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/09/2017 | Horizon Pharma plc | RAYOS (Drug), RAYOS, RAYOS | Food and Beverage | In-kind items and services | $7.42 | General |
| Category: RAYOS | ||||||
| 01/05/2017 | PFIZER INC. | VIAGRA (Drug), CHANTIX, ELIQUIS | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: GENITOURINARY (SEXUAL HEALTH);CARDIOVASCULAR;RESPIRATORY | ||||||
| 01/05/2017 | Novo Nordisk Inc | Victoza (Drug), Tresiba | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: Diabetes | ||||||
| 01/03/2017 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Travel and Lodging | In-kind items and services | $167.63 | General |
| Category: Respiratory | ||||||
| 01/03/2017 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $115.09 | General |
| Category: Respiratory | ||||||
| 01/03/2017 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $43.33 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,098 | 1,731 | $207,040 | $94,214 |
| 2022 | 9 | 1,158 | 1,800 | $218,995 | $97,757 |
| 2021 | 9 | 1,088 | 1,689 | $197,500 | $94,418 |
| 2020 | 11 | 985 | 1,596 | $183,767 | $75,792 |
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 242 | 562 | $84,300 | $32,562 | 38.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 209 | 209 | $52,045 | $28,176 | 54.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 127 | 193 | $40,380 | $17,150 | 42.5% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 22 | 26 | $8,450 | $6,026 | 71.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 274 | 507 | $10,140 | $4,259 | 42.0% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 173 | 173 | $5,190 | $3,372 | 65.0% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 14 | 14 | $3,430 | $2,269 | 66.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 26 | 30 | $2,850 | $304.75 | 10.7% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 11 | 17 | $255.00 | $95.28 | 37.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 251 | 598 | $89,700 | $33,638 | 37.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 221 | 221 | $54,105 | $30,650 | 56.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 126 | 194 | $40,740 | $17,651 | 43.3% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2022 | 21 | 25 | $8,125 | $5,922 | 72.9% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 189 | 189 | $5,670 | $3,724 | 65.7% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2022 | 18 | 18 | $4,410 | $2,957 | 67.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 285 | 508 | $10,160 | $1,501 | 14.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $2,760 | $1,345 | 48.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 35 | 35 | $3,325 | $368.60 | 11.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 235 | 518 | $77,700 | $32,470 | 41.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 201 | 201 | $49,120 | $28,755 | 58.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 125 | 196 | $39,060 | $18,193 | 46.6% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 20 | 27 | $8,775 | $6,424 | 73.2% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 184 | 184 | $5,520 | $3,725 | 67.5% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2021 | 18 | 18 | $4,410 | $2,996 | 67.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 269 | 500 | $10,000 | $1,497 | 15.0% |
About Dr. Bruce Morrison, D.O
Dr. Bruce Morrison, D.O is a Sports Medicine healthcare provider based in Huntingdon Valley, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255449476.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Morrison, D.O has received a total of $51,581 in payments from pharmaceutical and medical device companies, with $6,293 received in 2024. These payments were reported across 1,274 transactions from 60 companies. The most common payment nature is "Food and Beverage" ($19,835).
As a Medicare-enrolled provider, Morrison has provided services to 4,329 Medicare beneficiaries, totaling 6,816 services with total Medicare billing of $362,182. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Practice Information
- Specialty Sports Medicine
- Location Huntingdon Valley, PA
- Active Since 08/28/2006
- Last Updated 07/08/2007
- Taxonomy Code 207QS0010X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255449476
Products in Payments
- UBRELVY (Drug) $8,749
- AIRSUPRA (Drug) $8,478
- BEVESPI AEROSPHERE (Drug) $7,289
- Trintellix (Drug) $5,438
- FARXIGA (Drug) $1,969
- XIFAXAN (Drug) $848.95
- VRAYLAR (Drug) $762.52
- TRELEGY ELLIPTA (Drug) $723.33
- Vascepa (Drug) $595.39
- JARDIANCE (Drug) $557.87
- NURTEC ODT (Drug) $501.13
- Ozempic (Drug) $430.30
- ELIQUIS (Drug) $418.63
- Kerendia (Drug) $405.10
- Edarbi (Drug) $391.51
- Aimovig (Biological) $376.94
- Cologuard Collection Kit (Device) $318.46
- VYVANSE (Drug) $302.14
- XARELTO (Drug) $298.82
- TRINTELLIX (Drug) $292.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.